Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-76fb5796d-5g6vh Total loading time: 0 Render date: 2024-04-29T21:03:12.884Z Has data issue: false hasContentIssue false

Chapter 13 - Antidepressants and movement disorders

Published online by Cambridge University Press:  05 July 2015

By
Gilles Fénelon
Edited by
Joseph H. Friedman
Joseph H. Friedman
Affiliation:
Department of Neurology, Brown University
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Medication-Induced Movement Disorders , pp. 141 - 149
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Kessler, RC, Bromet, EJ. The epidemiology of depression across cultures. Annu Rev Public Health 2013; 34: 119–38.CrossRefGoogle ScholarPubMed
Berton, O, Nestler, EJ. New approaches to andidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006; 7: 137–51.CrossRefGoogle ScholarPubMed
Ciraulo, DA, Shader, RI, Greenblatt, DJ. Clinical pharmacology and therapeutics of antidepressants. In: Ciraulo, DA, Shader, RI, eds, Pharmacology of depression, DOI 10.1007/978-1-60327-435-7_2, Springer Science+Business Media, LLC 2011CrossRefGoogle Scholar
Leucht, C, Huhn, M, Leucht, S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev 2012; 12: CD009138.Google ScholarPubMed
Edwards, JG, Anderson, I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57: 507–33.CrossRefGoogle ScholarPubMed
Watanabe, N, Omori, IM, Nakagawa, A, et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs 2010; 24: 35–53.CrossRefGoogle ScholarPubMed
Serrano-Dueñas, M. Fluoxetine-induced tremor: clinical features in 21 patients. Parkinsonism Relat Disord 2002; 8: 325–7.CrossRefGoogle ScholarPubMed
Zeuner, KE, Deuschl, G. An update on tremors. Curr Opin Neurol 2012; 25: 475–482.CrossRefGoogle ScholarPubMed
Morgan, JC, Sethi, KD. Drug-induced tremors. Lancet 2005; 4: 866–76.Google ScholarPubMed
Burkhard, PR. Acute and subacute drug-induced movement disorders. Parkinsonism Relat Disord 2014; 20S1: S108–12.Google Scholar
Raethjen, J, Lemke, MR, Lindemann, M, Wenzelburger, R, Krack, P, Deuschl, G. Amitriptyline enhances the central component of physiological tremor. J Neurol Neurosurg Psychiatry 2001; 70: 78–82.CrossRefGoogle ScholarPubMed
Meltzer, HY, Young, M, Metz, J, Fang, VS, Schyve, PM, Arora, RC. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979; 45: 165–75.CrossRefGoogle ScholarPubMed
Vandel, P, Bonin, B, Leveque, E, Sechter, D, Bizouard, P. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol 1997; 7: 207–12.CrossRefGoogle ScholarPubMed
Gill, HS, DeVane, CL, Risch, SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol 1997; 17: 377–89.CrossRefGoogle ScholarPubMed
Madhusoodanan, S, Alexeenko, L, Sanders, R, Brenner, R. Extrapyramidal symptoms associated with antidepressants. A review of the literature and an analysis of spontaneous reports. Ann Clin Psychiatry 2010; 22: 148–56.Google Scholar
Bondon-Guitton, E, Perez-Lloret, S, Bagheri, H, Brefel, C, Rascol, O, Montatsruc, JL. Drug-induced parkinsonism: a review of 17 years experience in a regional pharmacovigilance center in France. Mov Disord 2011; 26: 2226–31.CrossRefGoogle Scholar
Strang, RR. Imipramine in treatment of parkinsonism: a double-blind placebo study. Brit Med J 1965; 2: 33–34.CrossRefGoogle ScholarPubMed
Laitinen, L. Desipramine in treatment of Parkinson’s disease. A placebo-controlled study. Acta Neurol Scand 1969; 45: 109–13.Google ScholarPubMed
Paumier, KL, Siderowf, AD, Auinger, P, et al. Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson’s disease. Mov Disord 2012; 27: 880–7.CrossRefGoogle ScholarPubMed
Leo, RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57: 449–54.CrossRefGoogle ScholarPubMed
Spigset, O. Adverse reactions of selective serotonin reuptake inhibitors: reports from a spontaneous reporting system. Drug Saf 1999; 20: 277–87.CrossRefGoogle ScholarPubMed
Hedenmalm, K, Güzey, C, Dalh, ML, Yue, QY, Spigset, O. Risk factors for extrapyramidal symptoms during treatment with selective serotonin reuptake inhibitors, including cytochrome P-450 enzyme, and serotonin and dopamine transporter and receptor polymorphisms. J Clin Psychopharmacol 2006; 26: 192–7.CrossRefGoogle ScholarPubMed
Montastruc, JL, llau, ME, Rascol, O, Senard, JM. Drug-induced parkinsonism: a review. Fundam Clin Pharmacol 1994; 8: 293–306.CrossRefGoogle ScholarPubMed
García-Parujuà, P, de Ugarte, L, Baca, E. More data for the CYP2D6 hypothesis? The in vivo inhibition of CYP2D6 isoenzyme and extrapyramidal symptoms induced by antidepressants in the elderly. J Clin Psychopharmacol 2004; 24: 111–2.Google Scholar
Montastruc, J-L, Fabre, N, Blin, O, Senard, J-M, Rascol, O, Rascol, A. Does fluoxetine aggravate Parkinson’s disease? A pilot prospectice study. Mov Disord 1995; 10: 355–7.CrossRefGoogle Scholar
Hauser, RA, Zesiewicz, TA. Sertraline for the treatment of depression in Parkinson’s disease. Mov Disord 1997; 12: 756–759.CrossRefGoogle ScholarPubMed
Ceravolo, R, Nuti, A, Piccinni, A, et al. Paroxetine in Parkinson’s disease: effects on motor and depressive symptoms. Neurology 2000; 55: 1216–8.CrossRefGoogle ScholarPubMed
Dell’Agnello, G, Ceravolo, R, Nuti, A, et al. SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study; Clin Neuropharmacol 2001; 24: 221–7.Google Scholar
Tesi, S, Antonini, A, Canesi, M, Zecchinelli, A, Mariani, CB, Pezzoli, G. Tolerability of paroxetine in Parkinson’s disease: a prospective study. Mov Disord 2000; 15: 986–9.Google Scholar
van de Vijer, DAMC, Roos, RAC, Jansen, PAF, Porsius, AJ, de Boer, A. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol 2002; 54: 168–170.CrossRefGoogle Scholar
Skapinakis, P, Bakola, E, Salanti, G, Lewis, G, Krytsis, AP, Mavreas, V. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurol 2010; 10: 49.CrossRefGoogle ScholarPubMed
Devos, D, Dujardin, K, Poirot, I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled study. Mov Disord. 2008; 23: 850–7.CrossRefGoogle ScholarPubMed
Richard, IH, McDermott, MP, Kurlan, R. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012; 78: 1229–36.CrossRefGoogle ScholarPubMed
Perez-Lloret, S, Rascol, O. Serotonin reuptake inhibitors for depression in PD. Nat Rev Neurol 2012; 8: 365–6.CrossRefGoogle ScholarPubMed
Esposito, E, Di Matteo, V, Di Giovanni, G. Serotonin-dopamine interaction: an overview. Progress Brain Res 2008; 172: 3–6.CrossRefGoogle ScholarPubMed
Zubenko, GS, Cohen, BM, Lipinski, JF Jr. Antidepressant-related akathisia. J Clin Psychopharmacol 1987; 7: 254–7.CrossRefGoogle ScholarPubMed
Lipinski, JF Jr, Mallya, G, Zimmerman, P, Pope, HG Jr. Fluoxetine-induced akathisia: clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339–42.Google ScholarPubMed
Lucire, Y, Crotty, C. Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family. Pharmacogenomics Pers Med 2011; 4: 65–81.Google ScholarPubMed
Markoula, S, Konistiotis, S, Chatzistafanidis, D, Lagos, G, Krytsis, AP. Akathisia induced by mirtazapine after 20 years of continuous treatment. Clin Neuropharmacol 2010; 33: 50–1.CrossRefGoogle ScholarPubMed
Stryjer, R, Rosenzcwaig, S, Bar, F, Ulman, AM, Weizman, A, Spivak, B. Trazodone for the treatment of neuroleptic-induced acute akathisia: a placebo-controlled, double-blind, crossover study. Clin Neuropharmacol 2010; 33: 219–22.CrossRefGoogle ScholarPubMed
Hansen, L. Fluoxetine dose-increment related akathisia in depression: implications for clinical care, recognition and management of selective serotonin reuptake inhibitor-induced akathisia. J Psychopharmacol 2003; 17: 451–2.CrossRefGoogle ScholarPubMed
Ohayon, MM, Roth, T. Prevalence of restless legs syndrome and periodic limb movement disorder in the general population. J Psychosom Res 2002; 53: 547–554.CrossRefGoogle ScholarPubMed
Rottach, KG, Schaner, BM, Kirch, MH, et al. Restless legs syndrome as side effect of second generation antidepressants. J Psychiatr Res 2009; 43: 70–5.Google Scholar
Högl, B, Kiechl, S, Willeit, J, et al. Restless syndrome. A community-based study of prevalence, severity, and risk factors. Neurology 2005; 64: 1920–24.CrossRefGoogle ScholarPubMed
Brown, LK, Decrick, DL, Doggett, JW, Guido, PS. Antidepressant medication use and restless legs syndrome in patients presenting with insomnia. Sleep Med 2005; 6: 443–50.CrossRefGoogle ScholarPubMed
Dimmitt, SB, Riley, GJ. Selective serotonin receptor uptake inhibitors can reduce restless legs symptoms. Arch Intern Med 2000; 160: 147.CrossRefGoogle ScholarPubMed
Baughman, KR, Bourguet, CC, Ober, SK. Gender differences in the association between antidepressant use and restless legs syndrome. Mov Disord 2009; 24: 1054–9.CrossRefGoogle ScholarPubMed
Picchietti, D, Winkelmann, JW. Restless legs syndrome, periodic limb movements in sleep, and depression. Sleep 2005; 28: 891–98.Google ScholarPubMed
Li, Y, Mirzaei, F, Eilis, J, et al. Prospective study of restless legs syndrome and risk of depression in women. Am J Epidemiol 2012; 176: 279–88.CrossRefGoogle ScholarPubMed
Page, RL II, Ruscin, JM, Bainbridge, JL, Brieke, AA. Restless legs syndrome induced by escitalopram: case report and review of the literature. Pharmacotherapy 2008; 28: 271–80.CrossRefGoogle ScholarPubMed
Bayard, M, Bailey, B, Acharya, D, et al. Bupropion and restless legs syndrome: a randomized controlled trial. J Am Board Fam Med 2011; 24: 422–8.CrossRefGoogle ScholarPubMed
Freeman, AA, Rye, DB. The molecular basis of restless legs syndrome. Curr Opin Neurobiol 2013; 23: 895–900.CrossRefGoogle ScholarPubMed
Jhoo, JH, Yoon, I-Y, Kim, YK, et al. Availability of brain serotonin transporters in patients with restless legs syndrome. Neurology 2010; 74: 513–8.CrossRefGoogle ScholarPubMed
Armitage, R, Trived, M, Rush, JA. Fluoxetine and oculomotor activity during sleep in depressed patients. Neuropsychopharmacol 1995; 12: 159–65.CrossRefGoogle ScholarPubMed
Dorsey, CM, Lukas, SE, Cunningham, SL. Fluoxetine-induced sleep disturbance in depressed patients. Neuropsychopharmacol 1996; 14: 437–42.CrossRefGoogle ScholarPubMed
Salin-Pascual, RJ, Galicia-Polo, L, Drucker-Colin, R. Sleep changes after 4 consecutive days of venlafaxine administration in normal volunteers. J Clin Psychiatry 1997; 58: 348–50.CrossRefGoogle ScholarPubMed
Yang, C, White, DP, Winkelman, JW. Antidepressants and periodic leg movements of sleep. Biol Psychiatry 2005; 58: 510–4.CrossRefGoogle ScholarPubMed
Vendrame, M, Zarowski, M, Loddenkemper, T, Steinborn, B, Kothare, SV. Selective serotonin reuptake inhibitors and periodic limb movements of sleep. Pediatr Neurol 2011; 45: 175–7.CrossRefGoogle ScholarPubMed
Zhang, B, Hao, Y, Jia, F, et al. Sertraline and periodic limb movements during sleep: an 8-week open-label study in depressed patients with insomnia. Sleep Med 2013; 14: 1405–12.CrossRefGoogle ScholarPubMed
Fulda, S, Kloiber, S, Dose, T, et al. Mirtazapine provokes periodic leg movements during sleep in young healthy men. Sleep 2013; 36: 661–9.CrossRefGoogle ScholarPubMed
Lane, R, Baldwin, D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997; 17: 208–21.CrossRefGoogle ScholarPubMed
Talarico, G, Tosto, G, Pietracupa, S, et al. Serotonin toxicity: a short review of the literature and two case reports involving citalopram. Neurol Sci 2011; 32: 507–9.CrossRefGoogle Scholar
Pedavally, S, Fugate, JE, Rabisntein, AA. Serotonin syndrome in the intensive care unit: clinical presentations and precipitating medications. Neurocrit Care 2014; 21: 108–113.CrossRefGoogle ScholarPubMed
Dunkley, EJC, Isbister, GK, Sibbritt, D, Dawson, AH, Whyte, IM. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J Med 2003; 96: 635–42.CrossRefGoogle ScholarPubMed
Dosi, R, Ambaliya, A, Joshi, H, Patell, R. Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary. BMJ Case Rep 2014 pii: bcr2014204154.CrossRefGoogle Scholar
Schillevoort, I, van Puijenbroek, EP, de Boer, A, Roos, RAC, Jansen, PAF, Leufkens, HGM. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. Int Clin Psychopharmacol 2002; 17: 75–9.CrossRefGoogle ScholarPubMed
Mcneill, A. Chorea induced by low-dose trazodone. Eur Neurol 2006; 55:101–102.CrossRefGoogle ScholarPubMed
Hüther, R, Gebhart, C, Mirisch, S, Bäuml, J, Förstl, H. Choreatic symptoms during and after treatment with paleperidone and escitalopram. Pharmacopsychiatry 2008; 41: 203–4.CrossRefGoogle ScholarPubMed
Como, PG, Rubin, AJ, O’Brien, CF et al. A controlled trial study in nondepressed patients with Huntington’s disease. Mov Disord 1997; 12: 397–401.CrossRefGoogle ScholarPubMed
Gerber, PE, Lynd, LD. Selective serotonin reuptake inhibitor-induced movement disorders. Ann Pharmacother 1998; 32: 692–8.CrossRefGoogle ScholarPubMed
Chen, P-Y, Lin, P-Y, Tien, S-C, Chang Y-Y, Lee Y. Duloxetine-related tardive dystonia and tardive dyskinesia: a case report. Gen Hosp Psychiatry 2010; 32: 646–9.CrossRefGoogle ScholarPubMed
Ellison, JM, Stanziani, P. SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry 1993; 54: 432–4.Google ScholarPubMed
Falisi, G, Rastelli, C, Panti, F, Maglione, H, Quezada Arcega, R. Psychotropic drugs and bruxism. Expert Opin Drug Saf 2014; 13: 1319–26.CrossRefGoogle ScholarPubMed
Bostwick, JM, Jaffee, MS. Buspirone as an antidote to SSRI-induced bruxism in 4 cases. J Clin Psychiatry 1999; 60: 857–60.CrossRefGoogle ScholarPubMed
Jiménez-Jiménez, FJ, Puertas, I, de Toledo-Heras, M. Drug-induced myoclonus. Frequency, mechanisms and management. CNS Drugs 2004; 18: 93–104.CrossRefGoogle ScholarPubMed
Garvey, MJ, Tollefson, GD. Occurrence of myoclonus in patients treated with cyclic antidepressants. Arch Gen Psychiatry 1987; 44: 269–72.CrossRefGoogle ScholarPubMed
Brefel-Courbon, C, Gardette, V, Ory, F, Montastruc, J-L. Drug-induced myoclonus: a French phamacovigilance database study. Neurophysiol Clin 2006; 36: 333–6.CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×